Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor
• * Advanced disease
• * Refractory to standard therapy OR no standard therapy exists
• Measurable or evaluable disease
• No active brain metastases
• * Previously treated (e.g., surgery or radiotherapy) brain metastases are allowed provided they are currently asymptomatic and inactive by CT scan or MRI
• PATIENT CHARACTERISTICS:
• Performance status
• ECOG 0-2
• Life expectancy
• At least 4 months
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 8 g/dL
• Hepatic
• Bilirubin normal
• Meets 1 of the following criteria:
• * Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)
• * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
• * AP ≤ 5 times ULN AND AST or ALT normal
• Renal
• Creatinine ≤ 2 mg/dL
• Cardiovascular
• No New York Heart Association class III or IV heart disease
• Immunologic
• No prior desquamating rash or ≥ grade 2 allergic reaction while receiving thalidomide
• No history of hypersensitivity to docetaxel or other drugs formulated in polysorbate 80
• No history of allergic reaction to compounds of similar chemical or biologic composition to study drugs
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other uncontrolled illness or other condition that would preclude study compliance
• No peripheral neuropathy ≥ grade 2
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent hematopoietic growth factors during course 1 of study treatment
• No concurrent immunotherapy
• Chemotherapy
• At least 6 weeks since prior mitomycin or nitrosoureas
• * No more than 2 prior courses of mitomycin
• No other concurrent chemotherapy
• Radiotherapy
• No prior pelvic radiotherapy
• Other
• At least 4 weeks since prior anticancer therapy
• No concurrent warfarin for anticoagulation (heparin is allowed)
• Recovered from all prior treatment
• No other concurrent anticancer therapy except bisphosphonates
• No other concurrent investigational agents